Ottawa, ON / ACCESSWIRE / Apr 7, 2014 / - Avivagen Inc. (TSXV:
VIV), a wellness company developing and delivering products that
support and enhance the health and quality of life for animals and
the people who care for them, announces that it will be attending
important trade shows for the animal feed industries serving Asian
markets.
Held in Bangkok, Thailand from April 8 to 10, the events are
trade shows and conferences dedicated to specialist ingredients,
additives and equipment used in the formulation of livestock,
aquaculture and pet feeds. Three events are co-located at the
Bangkok International Trade and Exhibition Centre and held every
two years.
The co-located events are VICTAM Asia, a leading international
exhibition and conference for feed industry technologies, FIAAP -
concerning Feed Ingredients & Additives for the Asia Pacific
region and GRAPAS - relating to Grain Processing and Storage
solutions.
Avivagen's CEO, Cameron Groome, will be available for meetings
throughout the conferences, which its organizers characterize as
attended by visitors from all over the world: "The senior
executives - CEOs, directors, mill and transport managers,
nutritionists, veterinarians, feed formulators from feed mills,
integrators, co-operatives, large farms, fish farms, hatcheries,
petfood processors, etc."
Attendance at this event is important to support moving OxC-beta
through the process of commercialization as a novel, safe and
effective non-antibiotic feed supplement. The conferences provide
Avivagen with the opportunity to meet with current and prospective
customers and to address questions about OxC-beta - in relation to
published results of its prior studies, trials in process and
livestock applications.
OxC-beta will be available via the conferences, as it is
approved for sale in the Kingdom of Thailand. International
distribution enquiries should be directed to Avivagen, while
domestic supply requests can be made to the Thai distributor of
OxC-beta, Natural Nutrients Co. Ltd. Avivagen is committed to
supporting the commercialization of OxC-beta in Asia, with
commercial or trial relationships now disclosed in relation to
Thailand, Vietnam and Korea.
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company trading
on the TSX Venture Exchange under the ticker symbol "VIV". The
Company's goal is to develop and deliver scientifically-proven
solutions that can truly benefit companion and production animals
by employing natural mechanisms for maintaining good health.
Avivagen's targeted markets include Livestock Productivity and Pet
Wellness.
The company has sites located in partnership facilities of the
National Research Council of Canada (NRC) - in Ottawa, Ontario and
Charlottetown, Prince Edward Island. More information can be found
at www.avivagen.com.
About OxC-beta
Avivagen's proprietary and patent-protected technology is based
on its discoveries concerning carotenoid antioxidants. The novel
natural compounds discovered by Avivagen support the body's own
systems to maintain and enhance health, particularly by supporting
immune function. Avivagen's commercial-stage application of its
technology is Fully-Oxidized beta-Carotene (OxC-beta). OxC-beta
compounds occur naturally as carotenoid oxidation products in
vegetation, but in minute amounts. They have been developed to
support the health of companion animals and for use in the global
food animal market.
Research and study results indicate OxC-beta supports innate
immune function, which can help maintain good health. In pets,
OxC-beta supports overall vitality and energy, mobility and joint
function, skin, coat and gut. Results observed in food animals have
included healthier growth, better utilization of feed and decreased
mortality. In food animals, it is intended that use of OxC-beta
avoids the feeding of antibiotics.
The commercial products of Avivagen are OxC-beta for livestock,
Vivamune(TM) Health Chews and Oximunol(TM) Chewables.
About OxC-beta for Livestock
OxC-beta for Livestock is available as a 10% pre-mix sold in 1.0
or 5.0 Kg quantities for parts-per-million addition to animal
feeds, in accordance with producer-developed protocols. In past
studies, OxC-beta has been shown to support health and growth in
species such as fish, chicken, pigs and cattle. OxC-beta for
livestock is currently available for commercial sale in the Kingdom
of Thailand.
About Vivamune(TM) Health Chews - For dogs and cats
Vivamune(TM) Health Chews, containing Avivagen's proprietary
active ingredients, are scientifically-formulated chews for dogs
and cats. Vivamune(TM) Health Chews work with a pet's own immune
system to maintain overall health and well-being. They are sold in
re-sealable packages of 30 chews and are currently available in the
United States by ordering on-line at www.vivamunehealth.com.
About Oximunol(TM) Chewables - For dogs
Oximunol(TM) Chewables are scientifically-formulated chewable
tablets that contain Avivagen's proprietary, patented active
ingredient OxC-beta. OxC-beta has been shown to stimulate innate
cellular immunity and may thereby help to maintain overall health
and well-being. Oximunol(TM) Chewables are distributed by Bayer
Healthcare LLC and are available through veterinarians for dogs of
all ages in the United States.
Forward Looking Statements
This document includes certain forward-looking statements that
are based upon current expectations, which involve risks and
uncertainties associated with the business of Avivagen Inc. and the
environment in which the business operates. Any statements
contained herein that are not statements of historical facts may be
deemed to be forward-looking, including those identified by the
expressions "will", "anticipate", "believe", "plan", "estimate",
"expect", "intend", and similar expressions. Forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results or events to differ materially from
current expectations. Unless required by law, Avivagen Inc. assumes
no obligation to update the forward-looking statements, or to
update the reasons why actual results could differ from those
reflected in the forward-looking statements.
For more information:
Avivagen Inc.
Cameron Groome
CEO & President
c.groome@avivagen.com
100 Sussex Drive
Ottawa, Ontario
Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com
-----------------
|Copyright© 2014|
|Avivagen |
-----------------
SOURCE: Avivagen Inc.
Avivagen (TSXV:VIV)
Historical Stock Chart
From Jan 2025 to Feb 2025
Avivagen (TSXV:VIV)
Historical Stock Chart
From Feb 2024 to Feb 2025
